Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
| Market Cap | 493.71M+86.0% |
| Revenue (ttm) | 8.22M-51.0% |
| Net Income | -75.74M+43.8% |
| EPS | -0.58+57.7% |
| Shares Out | 139.66M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,650,636.642 |
| Open | 3.37 |
| Previous Close | 3.40 |
| Day's Range | 3.19 - 3.56 |
| 52-Week Range | 1.74 - 6.60 |
| Beta | 0.80 |
| Analysts | Buy |
| Price Target | 10.60(+199.86%) |
| Earnings Date | Nov 5, 2026 |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About ACRS
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ACRS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ACRS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ACRS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ACRS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ACRS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ACRS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ACRS
Estimated from each fund’s disclosed top holdings × AUM
ACRS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ACRS’s recent data — informational, not investment advice